Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC

GA Simkens, TR van Oudheusden, D Nieboer… - Annals of surgical …, 2016 - Springer
Background With the introduction of cytoreductive surgery (CRS) and hyperthermic
intraperitoneal chemotherapy (HIPEC), long-term survival can be achieved in selected …

Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic …

IS Frøysnes, SG Larsen, M Spasojevic… - Journal of surgical …, 2016 - Wiley Online Library
Background and Objectives Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) can offer long‐term survival to patients with resectable peritoneal …

Survival and prognostic factors for metachronous peritoneal metastasis in patients with colon cancer

H Nagata, S Ishihara, K Hata, K Murono… - Annals of surgical …, 2017 - Springer
Background The clinical course of metachronous peritoneal metastasis of colorectal origin is
poorly understood. In this retrospective study, we aimed to elucidate survival and prognostic …

Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—a systematic review

WF Morano, M Khalili, DS Chi… - Journal of surgical …, 2018 - Wiley Online Library
Background The field of cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) has suffered from a lack of clinical trials to validate its expanding …

[HTML][HTML] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection

J Esquivel - Journal of gastrointestinal oncology, 2016 - ncbi.nlm.nih.gov
Background Chemotherapy hyperthermic intraperitoneal chemotherapy (HIPEC) is playing
an ever increasing role in the management of colorectal cancer (CRC) with peritoneal …

Risk factors for appendiceal and colorectal peritoneal metastases

M Enblad, W Graf, H Birgisson - European Journal of Surgical Oncology, 2018 - Elsevier
Background Early diagnosis to target minimal volume disease has received increased
attention in the management of appendiceal and colorectal peritoneal metastases (PM). This …

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications …

T Charrier, G Passot, J Peron, C Maurice… - Annals of surgical …, 2016 - Springer
Background Treatment of peritoneal carcinomatosis (PC) using cytoreductive surgery (CRS)
and hyperthermic intraperitoneal chemotherapy (HIPEC) is recommended as curative …

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review

MS Parikh, P Johnson, JP Romanes… - Diseases of the Colon …, 2022 - journals.lww.com
BACKGROUND: Combined treatment modality of cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy is emerging as an alternative option for colorectal peritoneal …

Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer

F Mendoza-Moreno, M Diez-Alonso… - Journal of Clinical …, 2022 - mdpi.com
Objectives: The aim of this study was to analyze the prognostic factors of survival in patients
with peritoneal metastasis (PM) from colorectal cancer (CRC). The type of relationship …

Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: risk factors for ICU admission …

S Malfroy, F Wallet, D Maucort-Boulch, L Chardonnal… - Surgical oncology, 2016 - Elsevier
Background and objectives For patients suffering from peritoneal carcinomatosis,
cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the only …